Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK): a Prospective, Single Arm, Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

In 2015, five randomized trials showed efficacy of endovascular thrombectomy over standard medical care in patients with acute ischemic stroke caused by occlusion of arteries of the proximal anterior circulation. However, sufficient recanalization (mTICI2b-3) can 't be acquired in all patients under thrombectomy. There is a lack of evidence that whether salvage intra-arterial thrombolysis is beneficial for patients with insufficient recanalization after endovascular thrombectomy. The EXTEND-IA TNK study indicated that tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. This study intends to explore the proportion of sufficient recanalization (2b/3) after intra-arterial tenecteplase administration in patients undergoing thrombectomy with insufficient recanalization (1/2a).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years;

• Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy;

• insufficient perfusion (mTICI 1/2a) after endovascular treatment;

• The availability of informed consent.

Locations
Other Locations
China
General Hospital of Northern Theater Command
RECRUITING
Shenyang
Contact Information
Primary
Zi-Ai Zhao, Doctor
zhaoziai@hotmail.com
+86 17790998175
Backup
Lin Tao, Master
1939908868@qq.com
+86 18802401698
Time Frame
Start Date: 2019-12-15
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 30
Treatments
Experimental: Intra-arterial administration of tenecteplase
Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
Related Therapeutic Areas
Sponsors
Leads: Hui-Sheng Chen

This content was sourced from clinicaltrials.gov

Similar Clinical Trials